A urologist working in an academic health centre writes:
We are indeed affected by the BCG shortage. We understand that Cancer Care Ontario is working on some recommendations for managing short supplies, and we have discussed our options in our group.
We have been told that our supply is ++ constrained and that future patients (for the time being), will need either a dosage decrease or a substituted drug, mitomycin C (neither as effective in studies).
The backorder is supposed to be resolved in late October.